Brokers Set Expectations for Scilex Holding’s Q4 2025 Earnings (NASDAQ:SCLX)

Scilex Holding (NASDAQ:SCLX) – Equities researchers at HC Wainwright reduced their Q4 2025 earnings estimates for Scilex in a research report issued on Thursday, May 23rd. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.01) per share for the quarter, down from their previous estimate of $0.03. HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Scilex’s current full-year earnings is ($0.63) per share.

Scilex (NASDAQ:SCLX) last announced its earnings results on Monday, March 11th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.04). The firm had revenue of $13.46 million for the quarter, compared to analyst estimates of $11.43 million.

Scilex Price Performance

Shares of SCLX stock traded down $0.03 on Friday, hitting $1.06. The stock had a trading volume of 211,652 shares, compared to its average volume of 931,368. Scilex has a 52-week low of $0.73 and a 52-week high of $8.30. The stock’s 50 day moving average is $1.15 and its 200-day moving average is $1.41.

Insider Buying and Selling at Scilex

In related news, insider Jaisim Shah acquired 83,061 shares of Scilex stock in a transaction on Thursday, May 16th. The shares were purchased at an average cost of $0.84 per share, for a total transaction of $69,771.24. Following the purchase, the insider now directly owns 98,943 shares of the company’s stock, valued at approximately $83,112.12. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Scilex news, Director Jay Chun purchased 57,500 shares of Scilex stock in a transaction dated Friday, May 17th. The shares were bought at an average cost of $0.90 per share, for a total transaction of $51,750.00. Following the transaction, the director now owns 102,500 shares in the company, valued at approximately $92,250. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Jaisim Shah acquired 83,061 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The stock was purchased at an average cost of $0.84 per share, for a total transaction of $69,771.24. Following the acquisition, the insider now owns 98,943 shares in the company, valued at $83,112.12. The disclosure for this purchase can be found here. 8.73% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Scilex

Large investors have recently bought and sold shares of the stock. Collective Family Office LLC increased its stake in Scilex by 68.4% during the 1st quarter. Collective Family Office LLC now owns 21,950 shares of the company’s stock valued at $35,000 after buying an additional 8,918 shares during the period. Cannon Global Investment Management LLC acquired a new position in shares of Scilex in the 1st quarter worth approximately $40,000. Focus Financial Network Inc. ADV acquired a new position in shares of Scilex in the 4th quarter worth approximately $58,000. Bank of New York Mellon Corp acquired a new position in shares of Scilex in the 3rd quarter worth approximately $68,000. Finally, Donald L. Hagan LLC grew its stake in shares of Scilex by 49.1% in the 4th quarter. Donald L. Hagan LLC now owns 52,343 shares of the company’s stock worth $107,000 after purchasing an additional 17,245 shares during the last quarter. Institutional investors and hedge funds own 69.67% of the company’s stock.

About Scilex

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.